Sereno M.,San Sebastián University |
Moreno V.,Hospital Fundacion Jimenez Diaz Fundacion Jimenez Diaz |
Rubio J.M.,Precision Oncology Laboratory POL |
Rubio J.M.,IMDEA Madrid Institute for Advanced Studies |
And 6 more authors.
Anti-Cancer Drugs | Year: 2015
Lung adenocarcinoma includes recurrent activating oncogenic mutations (EGFR, EML4-ALK, ROS1) that have been associated with response to EGFR and ALK inhibitors. Platinum-based chemotherapy is the standard therapy for non-oncodrivers population. Sorafenib is a small molecule that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, VEGFR-2, VEGFR-3 and PDGFR approved for advanced renal cell and hepatocellular carcinoma (b, c). Many studies have evaluated sorafenib in advanced non-small-cell lung cancer (NSCLC), with different results. We present a case report of a patient with NSCLC and the BRAF G469R mutation who showed a dramatic response to sorafenib. Anti-Cancer Drugs 26:1004-1007 Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.